The first 60 days: Small-cell lung cancer
A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle. Below, week by week, is what OnCo's record of Small-cell lung cancer says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
Weeks 1 to 2
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
- Screening and diagnosisNCCN category SCLC guideline, staging workup, NCCN SCLC v2.2026
Low-dose CT screening in heavy smokers finds some SCLC but stage shift is limited; diagnosis by bronchoscopic or CT-guided biopsy; staging with PET/CT and brain MRI.
Biomarkers your report may list
DLL3 (not required for tarlatamab)B7-H3SCLC-A/N/P/I subtypes (research)Stage (limited vs extensive) is the dominant decisionB7-H3 (I-DXd trials)SSTR2 (RYZ101)Transcription-factor subtype (ASCL1/NEUROD1/POU2F3/YAP1, research)PD-L1 and TMB (not predictive in SCLC)SLFN11 (chemotherapy/PARP sensitivity, research)ctDNA (research)
Ask which of these were tested and what the results were; see the report reader for what each value means.
Tests and imaging linked to this cancer
How it is staged
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- PathologistNamed in the standard of care for: Extensive stage, Screening and diagnosis, Extensive stage, first line.
- RadiologistNamed in the standard of care for: Limited stage, Screening and diagnosis, Very limited stage (T1-2 N0, ~5%), Brain metastases.
- SurgeonNamed in the standard of care for: Very limited stage (T1-2 N0, ~5%).
- Medical oncologistNamed in the standard of care for: Limited stage, Extensive stage, Relapsed, Very limited stage (T1-2 N0, ~5%) and 5 more.
- Clinical oncologist (radiotherapy)Named in the standard of care for: Limited stage, Very limited stage (T1-2 N0, ~5%), Extensive stage, first line, Brain metastases.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Chemoradiation → durvalumab; prophylactic cranial irradiation or MRI surveillance.
Lobectomy with mediastinal node dissection or SBRT, followed by adjuvant platinum-etoposide; PCI or MRI surveillance.
- 3.Limited stageNCCN category 1 (durvalumab consolidation, category 1), ESMO-MCBS A, NCCN SCLC v2.2026
Concurrent cisplatin-etoposide with thoracic radiotherapy (45 Gy twice daily or 60-70 Gy once daily), then durvalumab consolidation up to 2 years (ADRIATIC); PCI or MRI surveillance.
Platinum-etoposide + atezolizumab/durvalumab; lurbinectedin + atezolizumab maintenance.
- 5.Extensive stage, first lineNCCN category 1 (chemo-IO); 2A (lurbinectedin maintenance), ESMO-MCBS 3
Carboplatin-etoposide plus atezolizumab or durvalumab (4 cycles), then maintenance immunotherapy; lurbinectedin added to atezolizumab maintenance since 2025 (IMforte). Serplulimab-chemotherapy where approved. Consolidative thoracic radiotherapy for residual thoracic disease in good responders.
Whole-brain radiotherapy or, increasingly, stereotactic radiosurgery for limited numbers of lesions; PCI decisions individualised.
Platinum-etoposide, often with continued EGFR TKI; immunotherapy benefit uncertain; trials.
Tarlatamab (preferred), lurbinectedin, topotecan; I-DXd in trials.
Tarlatamab (preferred, OS benefit); platinum-etoposide rechallenge; lurbinectedin; topotecan.
Tarlatamab; lurbinectedin; topotecan; clinical trials (I-DXd, RYZ101, DLL3 bispecifics).
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example DLL3, B7-H3, SCLC-A/N/P/I subtypes, Stageis the dominant decision, B7-H3), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Limited-stage, Extensive-stage, SCLC-A.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Limited stage
- For my situation (limited stage), which of the standard options do you recommend and why?Guideline options include: Chemoradiation → durvalumab; prophylactic cranial irradiation or MRI surveillance.
- Am I a candidate for Durvalumab, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- For my situation (limited stage), which of the standard options do you recommend and why?Guideline options include: Concurrent cisplatin-etoposide with thoracic radiotherapy (45 Gy twice daily or 60-70 Gy once daily), then durvalumab consolidation up to 2 years (ADRIATIC); PCI or MRI surveillance.
- Am I a candidate for Platinum + etoposide (EP / CE), Durvalumab, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of ADRIATIC and CONVERT apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Extensive stage
- For my situation (extensive stage), which of the standard options do you recommend and why?Guideline options include: Platinum-etoposide + atezolizumab/durvalumab; lurbinectedin + atezolizumab maintenance.
- Am I a candidate for Atezolizumab, Durvalumab, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Relapsed
- For my situation (relapsed), which of the standard options do you recommend and why?Guideline options include: Tarlatamab (preferred), lurbinectedin, topotecan; I-DXd in trials.
- Am I a candidate for Tarlatamab, Ifinatamab deruxtecan, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of DeLLphi-304 apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Screening and diagnosis
- For my situation (screening and diagnosis), which of the standard options do you recommend and why?Guideline options include: Low-dose CT screening in heavy smokers finds some SCLC but stage shift is limited; diagnosis by bronchoscopic or CT-guided biopsy; staging with PET/CT and brain MRI.
Very limited stage (T1-2 N0, ~5%)
- For my situation (very limited stage (t1-2 n0, ~5%)), which of the standard options do you recommend and why?Guideline options include: Lobectomy with mediastinal node dissection or SBRT, followed by adjuvant platinum-etoposide; PCI or MRI surveillance.
- Am I a candidate for Platinum + etoposide (EP / CE), and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Extensive stage, first line
- For my situation (extensive stage, first line), which of the standard options do you recommend and why?Guideline options include: Carboplatin-etoposide plus atezolizumab or durvalumab (4 cycles), then maintenance immunotherapy; lurbinectedin added to atezolizumab maintenance since 2025 (IMforte). Serplulimab-chemotherapy where approved. Consolidative thoracic radiotherapy for residual thoracic disease in good responders.
- Am I a candidate for Platinum + etoposide (EP / CE), Atezolizumab, Durvalumab or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of IMpower133 and CASPIAN apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Relapsed, platinum-sensitive (≥90 days)
- For my situation (relapsed, platinum-sensitive (≥90 days)), which of the standard options do you recommend and why?Guideline options include: Tarlatamab (preferred, OS benefit); platinum-etoposide rechallenge; lurbinectedin; topotecan.
- Am I a candidate for Tarlatamab, Lurbinectedin, Topotecan, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of DeLLphi-304 apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Relapsed, platinum-resistant (<90 days)
- For my situation (relapsed, platinum-resistant (<90 days)), which of the standard options do you recommend and why?Guideline options include: Tarlatamab; lurbinectedin; topotecan; clinical trials (I-DXd, RYZ101, DLL3 bispecifics).
- Am I a candidate for Tarlatamab, Lurbinectedin, Topotecan or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of IDeate-Lung02 apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Brain metastases
- For my situation (brain metastases), which of the standard options do you recommend and why?Guideline options include: Whole-brain radiotherapy or, increasingly, stereotactic radiosurgery for limited numbers of lesions; PCI decisions individualised.
Transformed SCLC (from EGFR-mutant NSCLC)
- For my situation (transformed sclc (from egfr-mutant nsclc)), which of the standard options do you recommend and why?Guideline options include: Platinum-etoposide, often with continued EGFR TKI; immunotherapy benefit uncertain; trials.
- Am I a candidate for Platinum + etoposide (EP / CE), Osimertinib, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of Ifinatamab deruxtecan, Actinium-225 DOTATATE, Tarlatamab, PF-08634404?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “Rapid chemoresistance”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Brain metastases”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Trials open now for this cancer in OnCo, largest phase first. Joining a trial is a decision like any other: ask what the comparison arm is, whether a placebo is used, and what happens if you leave. The cancer page searches ClinicalTrials.gov live for more.
- A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)Phase 3 · active · NCT06698042A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS 50% or Greater
- A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Phase 3 · recruiting · NCT07513376A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)
- A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)Phase 3 · recruiting · NCT05989542An Open, Multi-center, Single-arm Phase IIIb Confirmatory Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Vebreltinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Exon 14 Mutation
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NPhase 3 · recruiting · NCT06627647A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-sPhase 3 · recruiting · NCT06692738A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Small-cell lung cancer: the full pageA fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
Words this page and the cancer page use
- Limited-stage vs extensive-stage (small-cell lung cancer): Small-cell lung cancer uses a two-way split instead of the usual four stages: limited (confined to one side of the chest and treatable within one radiation field, about a third of patients) or extensive (everything else).
- Overall survival (OS): Overall survival (OS) is how long patients live, full stop.
- Prophylactic cranial irradiation (PCI): Giving the brain a preventive dose of radiation (25 Gy in 10 sessions) before any metastasis can be seen, mainly in small-cell lung cancer, which spreads to the brain in over half of patients.
- Neuroendocrine tumour grade (Ki-67) and WHO classification: How fast the tumour cells are dividing, measured by Ki-67 staining, separates slow-growing neuroendocrine tumours from aggressive neuroendocrine carcinomas and decides the treatment.
- Progression-free survival (PFS): Progression-free survival (PFS) is how long patients live without their cancer growing.
- Consolidation therapy: Treatment given after a good response to kill the cancer cells that are presumably left but cannot be seen, to make the remission last.
- Platinum-sensitive / platinum-resistant: Whether a cancer that responded to platinum chemotherapy came back more than six months later (sensitive, so platinum can be used again) or sooner (resistant, so something else is needed).
- Differentiation: How closely a cancer cell still resembles the mature, specialised tissue it came from.
- Bronchoscopy (EBUS, robotic navigation): Passing a camera down the windpipe into the lungs to biopsy tumours and lymph nodes without surgery.
- Radiation pneumonitis and lung fibrosis: Inflammation of the lung one to six months after chest radiotherapy, causing cough, breathlessness and fever; usually settles with steroids but can leave permanent scarring.
Every term links to the glossary.